An Ex Vivo Method of Generating Super Regulatory T Cells as a Cell-based Therapy for the Prevention of Graft-vs-Host Disease
Lisa M. Minter, Ph.D. and Gregory N. Tew, Ph.D.
• Cell-based therapy for the prevention of graft-versus-host disease
• Simple, well-defined generation of personalized, cell-based therapy for the prevention of graft-versus-host disease
• Generation of super regulatory T cells with greatly improved suppressive capacity.
Regulatory T cells maintain immunological tolerance and dampen inflammatory responses. Administering regulatory T cells can prevent the immune-mediated tissue destruction of graft-versus-host disease, which frequently accompanies hematopoietic stem cell transfer. This technology provides a simple and effective method to generate and expand a unique population of stable and highly suppressive regulatory T cells, which can be used as a cell-based therapy for the prevention of graft-versus-host disease.
Dr. Lisa M. Minter is an associate professor in the Department of Veterinary and Animal Sciences at the University of Massachusetts Amherst. Her research group focuses on studying the mechanisms of aberrant immune system responses and dissecting the mechamisms of (auto)immune-mediated diseases using animal models of immune-mediated bone marrow failure and graft-vs-host disease. Dr. Gregory N. Tew is a professor in the Department of Polymer Science and Engineering at the University of Massachusetts Amherst. His research interests include supramolecular polymer science, directed self-assembly, bioinspired and biomimetic structures, self-organization, well-defined macromolecular architectures, etc.
Available for Licensing and/or Sponsored Research
UMA 17-061
Patent Issued
|
